Orexo Dividend

Dividend criteria checks 0/6

Orexo hat in der Vergangenheit keine Dividende gezahlt.

Key information

n/a

Dividend yield

n/a

Payout ratio

Industry average yield	2.4%
Next dividend pay date	n/a
Ex dividend date	n/a
Dividend per share	n/a
Earnings per share	-kr3.72
Dividend yield forecast in 3Y	0%

Recent dividend updates

No updates

Recent updates

Orexo AB (publ)'s (STO:ORX) Business And Shares Still Trailing The Industry

Apr 03

We Think Orexo (STO:ORX) Has A Fair Chunk Of Debt

Dec 09

Orexo AB (publ)'s (STO:ORX) Intrinsic Value Is Potentially 24% Below Its Share Price

Jun 14

Is Orexo (STO:ORX) A Risky Investment?

Apr 27

Orexo AB (publ)'s (STO:ORX) Intrinsic Value Is Potentially 92% Above Its Share Price

Oct 19

Increases to Orexo AB (publ)'s (STO:ORX) CEO Compensation Might Cool off for now

Apr 06

Orexo (STO:ORX) Share Prices Have Dropped 22% In The Last Five Years

Mar 16

Nikolaj Sørensen Is The President & CEO of Orexo AB (publ) (STO:ORX) And They Just Picked Up 2.1% More Shares

Feb 17

Orexo AB (publ) (STO:ORX) Just Reported And Analysts Have Been Cutting Their Estimates

Jan 31

Does Orexo (STO:ORX) Have A Healthy Balance Sheet?

Jan 25

Stability and Growth of Payments

Fetching dividends data

Stabile Dividende: Es liegen keine ausreichenden Daten vor, um festzustellen, ob die Dividende je Aktie von ORX in der Vergangenheit stabil geblieben ist.

Wachsende Dividende: Unzureichende Daten, um festzustellen, ob die Dividendenzahlungen von ORX gestiegen sind.

Dividend Yield vs Market

Orexo Dividend Yield vs Market

How does ORX dividend yield compare to the market?
Segment	Dividend Yield
Company (ORX)	n/a
Market Bottom 25% (SE)	1.5%
Market Top 25% (SE)	4.2%
Industry Average (Pharmaceuticals)	2.4%
Analyst forecast in 3 Years (ORX)	0%

Bemerkenswerte Dividende: Es ist nicht möglich, die Dividendenrendite von ORX im Vergleich zu den unteren 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Hohe Dividende: Es ist nicht möglich, die Dividendenrendite von ORX im Vergleich zu den besten 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Earnings Payout to Shareholders

Abdeckung der Erträge: Unzureichende Daten zur Berechnung der Ausschüttungsquote von ORX, um festzustellen, ob die Dividendenzahlungen durch die Gewinne gedeckt sind.

Cash Payout to Shareholders

Cashflow-Deckung: Es ist nicht möglich, die Nachhaltigkeit der Dividende zu berechnen, da ORX keine Ausschüttungen gemeldet hat.

Discover strong dividend paying companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Orexo Dividend

Dividend criteria checks 0/6

Key information

Recent dividend updates

Recent updates

Orexo AB (publ)'s (STO:ORX) Business And Shares Still Trailing The Industry

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates fall by 127%

Orexo AB (Publ) Announces Board Resignations

President & CEO recently bought kr148k worth of stock

New major risk - Financial position

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Orexo AB (publ) to Report Q4, 2024 Results on Feb 06, 2025

We Think Orexo (STO:ORX) Has A Fair Chunk Of Debt

Orexo AB (Publ) Announces FDA Acceptance of New Drug Application Filing for OX124

Orexo AB (Publ) Announces FDA Acceptance of New Drug Application Filing for OX124

Independent Chairman of the Board recently bought kr361k worth of stock

No longer forecast to breakeven

Executive VP & CFO recently bought kr81k worth of stock

Third quarter 2023 earnings: Revenues exceed analyst expectations

Orexo AB (publ) Announces Changes in the Board of Directors

Orexo AB (publ), Annual General Meeting, Apr 26, 2024

Orexo AB (publ) Announces Data from the MODIA Study Evaluating Impact on Use of Illicit Opioids

Orexo AB (Publ) Announces Henrik Kjær Hansen Will Resign from the Board of Directors

Orexo AB (publ) to Report Q2, 2024 Results on Jul 17, 2024

Orexo AB (publ.) Submits New Drug Application to FDA for OX124, a High-Dose Rescue Medication for Opioid Over Overio Overio Overio Overio

President & CEO recently bought kr74k worth of stock

Second quarter 2023 earnings: Revenues exceed analyst expectations

New minor risk - Profitability

Forecast breakeven date pushed back to 2025

Orexo AB (publ)'s (STO:ORX) Intrinsic Value Is Potentially 24% Below Its Share Price

Price target decreased by 15% to kr31.00

First quarter 2023 earnings: Revenues exceed analyst expectations

Is Orexo (STO:ORX) A Risky Investment?

President & CEO recently bought kr189k worth of stock

Orexo AB (publ) Submits New Drug Application to FDA for OX124, A High-Dose Rescue Medication for Opioid Overdose

Full year 2022 earnings released: kr5.17 loss per share (vs kr6.51 loss in FY 2021)

Orexo AB (publ.) Initiates Exploratory Feasibility Studies of amorphOX with Two Leading Biopharmaceutical and Vaccine Companies

Orexo AB (publ) to Report Fiscal Year 2022 Final Results on Mar 28, 2023

Consensus forecasts updated

Third quarter 2022 earnings released

Orexo AB (publ) Announces Last Patient Enrolled in Pivotal Study Evaluating the Efficacy of MODIA® in Combination with Sublingual Buprenorphine/ Naloxone for the Treatment of OUD

Orexo AB (publ) Appoints Edward Kim, M.D., as New Chief Medical Officer

Orexo AB (publ)'s (STO:ORX) Intrinsic Value Is Potentially 92% Above Its Share Price

Orexo AB (publ), Annual General Meeting, Apr 18, 2023

Orexo Announces Positive Data from Phase 1 Clinical Study for OX640

Orexo AB (publ) to Report Q1, 2023 Results on Apr 27, 2023

Would Orexo (STO:ORX) Be Better Off With Less Debt?

Consensus forecasts updated

Independent Director recently bought kr60k worth of stock

Second quarter 2022 earnings released

Orexo AB (Publ.) Announces Successfully Initiated the First Explorative Human Clinical Study for Ox640

Are Investors Undervaluing Orexo AB (publ) (STO:ORX) By 47%?

Consensus estimates of losses per share improve by 22%

First quarter 2022 earnings: Revenues in line with analyst expectations

Price target decreased to kr28.00

Orexo AB (publ) Announces Board Appointments

Is Orexo (STO:ORX) Using Too Much Debt?

Full year 2021 earnings: EPS exceeds analyst expectations

Director recently bought kr505k worth of stock

Consensus forecasts updated

Price target decreased to kr54.00

President & CEO recently bought kr243k worth of stock

Full year 2021 earnings: EPS exceeds analyst expectations

Orexo AB (publ) to Report Q4, 2022 Results on Jan 26, 2023

Orexo AB (Publ.) Develops Nasal Adrenaline Medication Based on the Novel Amorphox Platform

Orexo AB Provides Information About Its New Proprietary Drug Delivery Platform - Amorphox

Third quarter 2021 earnings released: kr1.52 loss per share (vs kr2.45 loss in 3Q 2020)

Consensus EPS estimates fall to -kr5.18

Second quarter 2021 earnings released: kr2.15 loss per share (vs kr0.94 loss in 2Q 2020)

Orexo AB (Publ) Pharmaceutical Pipeline Asset Ox124 Enters Pivotal Trial

Orexo Announces First Patient Enrolled in Pivotal Study Evaluating the Efficacy of Modia™ in Combination with Sublingual Buprenorphine/ Naloxone for the Treatment of OUD

Independent Director recently bought kr61k worth of stock

Independent Director recently bought kr103k worth of stock

Independent Chairman of the Board recently bought kr409k worth of stock

Independent Chairman of the Board recently bought kr409k worth of stock

Consensus forecasts updated

President & CEO recently bought kr400k worth of stock

Orexo (STO:ORX) Has Debt But No Earnings; Should You Worry?

First quarter 2021 earnings released